Goldman Sachs Group Inc. Has $847,000 Holdings in Astria Therapeutics, Inc. $ATXS

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Astria Therapeutics by 26.8%, holding approximately $847,000 in shares after selling 57,954 during the first quarter.
• Astria Therapeutics has a market capitalization of $420.48 million with a current stock price of $7.45, reflecting a 0.8% decline recently.
• Analysts have set a consensus buy rating for Astria Therapeutics with an average target price of $30.20, indicating positive sentiment regarding its future performance.

Goldman Sachs Group Inc. decreased its position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 26.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 158,588 shares of the biotechnology company's stock after selling 57,954 shares during the quarter. Goldman Sachs Group Inc. owned about 0.28% of Astria Therapeutics worth $847,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System grew its position in shares of Astria Therapeutics by 9.9% in the fourth quarter. California State Teachers Retirement System now owns 32,561 shares of the biotechnology company's stock valued at $291,000 after purchasing an additional 2,935 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Astria Therapeutics by 3.1% in the first quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company's stock valued at $815,000 after purchasing an additional 4,562 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $50,000. AlphaQuest LLC boosted its stake in shares of Astria Therapeutics by 100.9% in the first quarter. AlphaQuest LLC now owns 14,216 shares of the biotechnology company's stock valued at $76,000 after buying an additional 7,139 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Astria Therapeutics by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company's stock valued at $567,000 after buying an additional 7,756 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Stock Down 0.8%

NASDAQ ATXS opened at $7.45 on Wednesday. The company has a market capitalization of $420.48 million, a price-to-earnings ratio of -3.71 and a beta of 0.42. Astria Therapeutics, Inc. has a twelve month low of $3.56 and a twelve month high of $12.72. The stock has a fifty day simple moving average of $6.81 and a 200 day simple moving average of $5.77.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.04. Research analysts expect that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ATXS shares. HC Wainwright boosted their price target on Astria Therapeutics from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $49.00 price target on shares of Astria Therapeutics in a research note on Wednesday, September 17th. Citigroup reiterated an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, JMP Securities boosted their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company a "market outperform" rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $30.20.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

Want to see what other hedge funds are holding ATXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.